NMTC - NeuroOne Medical Technologies Corp Stock Price, Fair Value and News

1.13USD+0.01 (+0.89%)Market Closed

Market Summary

USD1.13+0.01

Market Closed

0.89%

NMTC Stock Price

View Fullscreen

NMTC RSI Chart

NMTC Valuation

Market Cap

29.0M

Price/Earnings (Trailing)

-2.16

Price/Sales (Trailing)

15.27

EV/EBITDA

-1.99

Price/Free Cashflow

-2.13

NMTC Price/Sales (Trailing)

NMTC Profitability

Operating Margin

-6.55%

EBT Margin

-689.99%

Return on Equity

-304.92%

Return on Assets

-231.38%

Free Cashflow Yield

-46.88%

NMTC Fundamentals

NMTC Revenue

Revenue (TTM)

2.0M

Rev. Growth (Yr)

-48.74%

NMTC Earnings

Earnings (TTM)

-13.5M

Earnings Growth (Yr)

-93.04%

Earnings Growth (Qtr)

-6.69%

Breaking Down NMTC Revenue

Last 7 days

-1.8%

Last 30 days

-6.7%

Last 90 days

-6.7%

Trailing 12 Months

-27.3%

How does NMTC drawdown profile look like?

NMTC Financial Health

Current Ratio

3.68

NMTC Investor Care

Shares Dilution (1Y)

58.46%

Diluted EPS (TTM)

-0.68

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	1.1M	1.5M	2.0M	0
2022	28.8K	100.0K	171.2K	616.5K
2021	1.0M	567.2K	114.0K	48.9K
2020	0	0	1.9M	1.5M
2014	1.6M	0	0	0
2013	331.1K	650.2K	969.3K	1.3M
2012	0	0	0	12.0K
2011	0	0	0	5.4K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of NeuroOne Medical Technologies Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 21, 2024	mertens steve	sold (taxes)	-8,337	1.15	-7,250	chief technology officer
Apr 21, 2024	christianson mark	sold (taxes)	-2,334	1.15	-2,030	business development director
Apr 21, 2024	rosa david a	sold (taxes)	-22,623	1.15	-19,673	ceo and president
Mar 31, 2024	mertens steve	sold (taxes)	-302	1.2	-252	chief technology officer
Mar 31, 2024	christianson mark	sold (taxes)	-108	1.2	-90.00	business development director
Mar 31, 2024	rosa david a	sold (taxes)	-2,686	1.2	-2,239	ceo and president
Feb 29, 2024	mertens steve	sold (taxes)	-304	1.21	-252	chief technology officer
Feb 29, 2024	christianson mark	sold (taxes)	-108	1.21	-90.00	business development director
Feb 29, 2024	rosa david a	sold (taxes)	-2,709	1.21	-2,239	ceo and president
Feb 18, 2024	mcclurg ronald w.	acquired	-	-	113,717	chief financial officer

Which funds bought or sold NMTC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 29, 2024	Princeton Global Asset Management LLC	unchanged	-	-6,396	20,200	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-41.1	-2,000	2,000	-%
Apr 15, 2024	Wealth Alliance Advisory Group, LLC	sold off	-100	-30,810	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	108	1,058,540	1,449,860	-%
Feb 26, 2024	Virtu Financial LLC	new	-	29,000	29,000	-%
Feb 15, 2024	Nantahala Capital Management, LLC	added	94.26	2,723,540	3,836,540	0.12%
Feb 14, 2024	STATE STREET CORP	unchanged	-	35,582	81,526	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	reduced	-70.00	-41.00	48.00	-%
Feb 14, 2024	Walleye Capital LLC	sold off	-100	-201,191	-	-%
Feb 14, 2024	AWM Investment Company, Inc.	reduced	-6.45	910,879	2,291,000	0.30%

Are Funds Buying or Selling NMTC?

Are funds buying NMTC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NMTC

No. of Funds

Unveiling NeuroOne Medical Technologies Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	nantahala capital management, llc	5.1%	1,214,094	SC 13G
Jan 11, 2024	lytton laurence w	5.2%	1,304,102	SC 13G
Aug 02, 2023	manchester management co llc	999%	2,364,052	SC 13G/A

Recent SEC filings of NeuroOne Medical Technologies Corp

View All Filings

Date Filed	Form Type	Document
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Apr 02, 2024	4	Insider Trading
Mar 26, 2024	8-K	Current Report
Mar 15, 2024	8-K	Current Report
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading

Peers (Alternatives to NeuroOne Medical Technologies Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	183.9B	40.1B	-5.62%	-2.90%	32.13	4.58	-8.12%	-17.45%
BDX	67.8B	19.5B	-5.66%	-11.68%	53.96	3.48	4.02%	-22.04%
ALGN	21.2B	3.9B	-7.04%	-6.30%	47.65	5.49	3.42%	23.09%
BAX	20.5B	14.8B	-4.91%	-14.77%	7.72	1.38	2.12%	209.17%
MID-CAP
ATR	9.6B	3.5B	1.73%	23.52%	30.58	2.7	6.16%	35.06%
HSIC	8.9B	12.3B	-3.30%	-9.63%	21.4	0.72	-2.44%	-22.68%
BIO	7.9B	2.7B	-19.88%	-38.53%	-12.36	2.95	-4.68%	82.43%
XRAY	6.2B	4.0B	-7.53%	-26.81%	-46.27	1.57	1.10%	85.84%
AXNX	3.4B	366.4M	-2.96%	16.48%	-559.61	9.27	33.86%	89.83%
PDCO	2.3B	6.6B	-5.97%	-4.09%	11.79	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-11.99%	-14.73%	-1.93	0.41	7.73%	-1066.14%
ANIK	383.9M	166.7M	2.24%	1.21%	-4.64	2.3	6.67%	-456.34%
ANGO	231.9M	324.0M	-0.85%	-30.05%	-1.21	0.72	-3.19%	-337.41%
APYX	49.5M	52.3M	2.94%	-58.82%	-2.65	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-18.45%	260.53%	-0.3	0.96	5.77%	8.23%

NeuroOne Medical Technologies Corp News

Latest updates

NeuroOne Medical Technologies Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2014Q1	2013Q4	2013Q3	2013Q2	2013Q1	2012Q4	2011Q4
Revenue	-100.0%	-	497,253	-	-	1,455,188	970,125	485,063	-	6,374	4,974	17,451	20,113	71,474	-	-	-	-	-	-	-	297
Cost Of Revenue	29.8%	711,335	548,125	386,240	434,673	126,886	83,850	38,462	72,807	46,844	65,466	61,935	39,363	109,131	-	-	-	-	-	-	-	-
Gross Profit	37.5%	266,314	193,655	243,666	31,503	-12,307	-15,062	-6,413	-36,223	-13,096	-17,130	-21,839	-21,123	-37,657	-	165	140	252	451	406	360	-
Operating Expenses	8.9%	3,656,789	3,358,399	3,753,901	3,527,422	3,227,233	3,327,632	2,755,021	3,023,587	2,802,603	2,631,967	3,030,608	2,394,681	2,128,018	2,043,991	-	-	-	-	-	-	-
S&GA Expenses	37.6%	2,173,472	1,579,035	1,862,389	1,821,108	1,663,737	1,889,398	1,529,670	1,818,207	1,742,141	1,623,680	2,129,474	1,313,252	1,193,860	1,259,275	-	-	-	-	-	-	-
R&D Expenses	-16.6%	1,483,317	1,779,364	1,891,512	1,706,314	1,563,496	1,438,234	1,225,351	1,205,380	1,060,462	1,008,287	901,134	1,081,429	934,158	784,716	-	-	-	-	-	-	-
EBITDA Margin	-13.6%	-6.79	-5.97	-6.59	-8.70	-14.26	-57.71	38.62	133	78.53	33.63	6.60	-5.05	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	6,106	-	-	-3,053	-77,811	-	-	-	-	-	-	-
Earnings Before Taxes	-6.7%	-3,344,900	-3,135,121	-3,468,773	-3,522,828	-1,732,769	-1,374,344	-2,759,727	-3,058,067	-2,807,475	-	-2,951,609	-2,393,916	-1,959,480	11,055,921	-	-	-	-	-	-	-
EBT Margin	-13.6%	-6.90	-6.07	-6.70	-8.84	-14.48	-58.42	37.52	130	76.69	32.90	6.61	-0.38	-	-	-	-	-	-	-	-	-
Net Income	-6.7%	-3,344,900	-3,135,121	-3,468,773	-3,522,828	-1,732,769	-1,374,344	-2,759,727	-3,058,067	-2,807,475	-2,643,163	-2,951,609	-2,393,916	-1,959,480	-566,392	-	-	-	-	-	-	-
Net Income Margin	-13.6%	-6.90	-6.07	-6.70	-8.84	-14.48	-58.42	-112	-397	-220	-87.26	-13.88	-11.77	-	-	-	-	-	-	-	-	-
Free Cashflow	-29.9%	-3,846,522	-2,960,446	-3,079,550	-3,727,230	-3,503,765	951,635	-2,690,858	-3,314,910	-2,740,627	-2,064,415	-2,319,329	-2,436,229	-1,960,591	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-28.1%	5,822	8,097	5,758	7,205	9,660	12,823	11,571	14,089	17,183	7,938	9,809	11,917	7,913	4,760	4,462	1,389	2,659	533	1,536	2,575	578
Current Assets	-30.4%	5,093	7,313	4,879	6,357	8,967	12,176	10,929	13,443	16,576	7,292	9,271	11,355	7,340	4,155	3,904	829	2,092	302	1,299	2,385	383
Cash Equivalents	-49.6%	2,681	5,322	3,083	3,602	4,667	8,160	10,178	12,869	16,184	6,901	8,991	11,274	7,129	4,036	3,824	747	2,044	261	1,247	2,305	351
Inventory	-6.8%	1,609	1,727	1,517	1,174	904	705	454	222	229	98.00	52.00	-	14.00	-	-	-	-	-	-	-	-
Net PPE	-3.9%	505	526	587	523	335	354	315	287	217	223	156	161	153	166	101	85.00	68.00	52.00	53.00	-	-
Liabilities	-24.0%	1,404	1,848	1,837	1,672	1,488	3,218	952	966	1,236	1,385	954	1,057	6,505	2,694	8,389	6,574	7,271	1,770	1,809	2,130	5,536
Current Liabilities	-22.8%	1,383	1,793	1,748	1,550	1,335	3,099	815	810	1,062	1,182	747	750	6,183	2,356	8,037	6,290	6,973	1,770	1,809	2,130	4,712
Short Term Borrowings	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	229	528
Shareholder's Equity	-29.3%	4,418	6,249	3,921	5,533	8,172	9,604	10,618	13,122	15,948	6,554	8,855	10,860	1,408	2,066	-	-	-	-	-	445	-
Retained Earnings	-5.3%	-66,031	-62,686	-59,551	-56,100	-52,559	-50,826	-49,452	-46,692	-43,634	-40,827	-38,184	-35,232	-32,838	-30,879	-30,312	-23,221	-21,875	-17,238	-15,885	-14,022	-11,810
Additional Paid-In Capital	2.2%	70,425	68,912	63,455	61,598	60,715	60,415	60,055	59,775	59,542	47,369	47,003	46,057	34,224	32,923	26,368	18,022	17,250	15,988	15,599	14,454	6,842
Shares Outstanding	3.8%	24,831	23,929	17,862	16,888	16,231	16,217	15,928	15,795	15,408	12,010	10,269	11,910	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	24,808	-	-	-	17,000	-	-	-	82,500	-	-	-	17,100	-	-	-	37,700	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-31.2%	-3,809	-2,902	-2,940	-3,551	-3,492	1,018	-2,636	-3,221	-2,679	-2,029	-2,289	-2,379	-1,904	273	-1,222	-1,250	-1,224	-1,142	-1,676	-1,876	-699
Share Based Compensation	13.8%	309	271	296	-	300	256	256	-	-	-	-	-	-	-	-	-	-	-97.08	232	70.00	119
Cashflow From Investing	25.9%	-37.13	-50.12	861	1,824	15.00	-3,035	-54.23	-93.32	-61.49	-35.11	-29.91	-	-	-56.36	-25.84	-29.95	-10.27	-4.40	-53.95	-	-
Cashflow From Financing	-76.8%	1,205	5,192	1,561	662	-15.71	-	-	-322*	12,024	-24.98	36.00	6,527	4,997	-3.87	4,325	-16.87	3,019	161	672	3,896	1,037

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NMTC Income Statement

2023-12-31

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Product revenue	$ 977,649	$ 114,579
Cost of product revenue	711,335	126,886
Product gross profit (loss)	266,314	(12,307)
Collaborations revenue		1,455,188
Operating expenses:
Selling, general and administrative	2,173,472	1,663,737
Research and development	1,483,317	1,563,496
Total operating expenses	3,656,789	3,227,233
Loss from operations	(3,390,475)	(1,784,352)
Other income	45,575	51,583
Loss before income taxes	(3,344,900)	(1,732,769)
Provision for income taxes
Net loss	$ (3,344,900)	$ (1,732,769)
Net loss per share:
Basic (in Dollars per share)	$ (0.14)	$ (0.11)
Number of shares used in per share calculations:
Basic (in Shares)	23,995,610	16,230,997

NMTC Balance Sheet

2023-12-31

Condensed Balance Sheets - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Current assets:
Cash and cash equivalents	$ 2,680,985	$ 5,322,493
Accounts receivable	543,399
Inventory	1,608,657	1,726,686
Prepaid expenses and other assets	259,966	263,746
Total current assets	5,093,007	7,312,925
Intangible assets, net	83,998	89,577
Right-of-use assets	140,198	169,059
Property and equipment, net	505,175	525,753
Total assets	5,822,378	8,097,314
Current liabilities:
Accounts payable	760,000	685,104
Accrued expenses and other liabilities	623,240	1,107,522
Total current liabilities	1,383,240	1,792,626
Operating lease liability, long term	20,982	55,284
Total liabilities	1,404,222	1,847,910
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding.
Common stock, $0.001 par value; 100,000,000 shares authorized; 24,831,090 and 23,928,945 shares issued and outstanding as of December 31, 2023 and September 30, 2023, respectively.	24,831	23,929
Additional paid–in capital	70,424,528	68,911,778
Accumulated deficit	(66,031,203)	(62,686,303)
Total stockholders’ equity	4,418,156	6,249,404
Total liabilities and stockholders’ equity	$ 5,822,378	$ 8,097,314

About NeuroOne Medical Technologies Corp

NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

CEO	Mr. David A. Rosa M.D.
WEBSITE	n1mtc.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	15

NeuroOne Medical Technologies Corp Frequently Asked Questions

What is the ticker symbol for NeuroOne Medical Technologies Corp? What does NMTC stand for in stocks?

NMTC is the stock ticker symbol of NeuroOne Medical Technologies Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NeuroOne Medical Technologies Corp (NMTC)?

As of Mon Apr 29 2024, market cap of NeuroOne Medical Technologies Corp is 29.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NMTC stock?

You can check NMTC's fair value in chart for subscribers.

What is the fair value of NMTC stock?

You can check NMTC's fair value in chart for subscribers. The fair value of NeuroOne Medical Technologies Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of NeuroOne Medical Technologies Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NMTC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is NeuroOne Medical Technologies Corp a good stock to buy?

The fair value guage provides a quick view whether NMTC is over valued or under valued. Whether NeuroOne Medical Technologies Corp is cheap or expensive depends on the assumptions which impact NeuroOne Medical Technologies Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NMTC.

What is NeuroOne Medical Technologies Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, NMTC's PE ratio (Price to Earnings) is -2.16 and Price to Sales (PS) ratio is 15.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NMTC PE ratio will change depending on the future growth rate expectations of investors.